Effect of Renal and Hepatic Diseases on Pharmacokinetics

This chapter discusses the impact of renal and hepatic diseases on pharmacokinetics. Antidiabetics, aminoglycosides, ACE inhibitors, and other drug pharmacokinetics, related to the diseases, are mentioned. Renal and hepatic diseases significantly alter the pharmacokinetics of drugs, necessitating dose adjustments to ensure efficacy and avoid toxicity. In renal impairment, decreased glomerular filtration rate (GFR) leads to prolonged drug half-life and reduced clearance, particularly for renally excreted drugs. This can result in drug accumulation and increased risk of adverse effects. Conversely, drugs primarily eliminated via hepatic metabolism may not be significantly affected by renal impairment. Hepatic diseases such as cirrhosis can compromise drug metabolism and hepatic blood flow, leading to altered drug clearance and increased bioavailability of certain medications. Impaired hepatic function reduces the activity of drug-metabolizing enzymes and hepatic transporters, prolonging drug half-life and necessitating dose adjustments to prevent toxicity. Understanding the impact of renal and hepatic diseases on pharmacokinetics is crucial for optimizing drug therapy in affected patients. Clinicians must adjust drug doses based on individual patient factors, including the severity of organ dysfunction and the drug’s pharmacokinetic properties. Close monitoring of drug levels and therapeutic outcomes is essential to ensure safe and effective treatment while minimizing the risk of adverse events. Pharmacokinetic considerations play a vital role in personalized medicine, guiding clinicians in tailoring drug therapy to each patient’s unique physiological characteristics and disease status.